MCM
BBIO icon

Monimus Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Monimus Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,859
Closed -$616K – 60
2025
Q3 		$616K Sell
11,859
-1,691
-12% -$82.5K 0.38% 50
2025
Q2 		$585K Sell
13,550
-10,210
-43% -$371K 0.43% 49
2025
Q1 		$821K Sell
23,760
-17,317
-42% -$584K 0.7% 37
2024
Q4 		$1.13M Buy
+41,077
New +$1.06M 1.06% 31

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Monimus Capital Management's BBIO Position: Q4 2025 in Review

Monimus Capital Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 11,859 shares — an estimated $616K sold.

Monimus Capital Management first reported a position in BBIO in Q4 2024 and held it in 4 quarters. The position peaked at $1.13M in Q4 2024. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Monimus Capital Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Monimus Capital Management sold 11,859 BridgeBio Pharma shares in Q4 2025, an estimated $616K.
  • Monimus Capital Management first reported a position in BridgeBio Pharma in Q4 2024 and held it in 4 quarters.
  • Monimus Capital Management's BridgeBio Pharma position peaked at $1.13M in Q4 2024.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Monimus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.